Screener
Cytek Biosciences, Inc. CTKB Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
| (In thousands, except share and per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other income (expense), net | (243) | 3,849 | 847 | 7,557 |
| Loss before income taxes | (11,643) | (6,775) | (29,016) | (18,041) |
| Provision for (benefit from) income taxes | 515 | (1,192) | 2,008 | (1,056) |
| Net loss | $(12,158) | $(5,583) | $(31,024) | $(16,985) |
| Net loss, basic and diluted | $(12,158) | $(5,583) | $(31,024) | $(16,985) |
| Net loss per share, basic and diluted | $(0.09) | $(0.04) | $(0.24) | $(0.13) |
| Weighted-average shares used in calculating net loss per share, basic and diluted | 129,460,518 | 126,934,294 | 129,084,814 | 127,632,999 |
| Comprehensive loss: |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s net income?
- Cytek Biosciences, Inc. (CTKB) reported net income of -$12.16M in Q2 2026.
- How has Cytek Biosciences, Inc.'s net income changed year-over-year?
- Cytek Biosciences, Inc.'s net income decreased by 117.8% year-over-year, from -$5.58M to -$12.16M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Cytek Biosciences, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude